Blood Res.  2024;59:29. 10.1007/s44313-024-00023-9.

Evaluation of FVIII pharmacokinetic profiles in Korean hemophilia A patients assessed with myPKFiT: a retrospective chart review

• Park Y
• Yoo K
• Park S
• Hwang T
• Jung A
• Choi E

• KMID: 2562533
• DOI: http://doi.org/10.1007/s44313-024-00023-9

Abstract

Purpose
This study aimed to investigate the pharmacokinetics (PK) of factor VIII (FVIII) in Korean patients, as limited information is available on the PK of FVIII in this population.
Methods
We collected the FVIII PK results from patients with moderate-to-severe hemophilia A using myPKFiT. PK variations were assessed according to age, blood type, inhibitor history, von Willebrand factor antigen (vWF:Ag) level, and body mass index. Additionally, the correlation between the PK profile and prophylaxis regimen was specifically analyzed for each product in severe cases.
Results
The PK data of 48 and 81 patients treated with octocog alfa and rurioctocog alfa pegol, respectively, were obtained. The median half-lives of octocog alfa and rurioctocog alfa pegol were 9.9 (range: 6.3–15.2) h and 15.3 (range: 10.4–23.9) h, respectively. The PK profiles for each product did not differ according to age group; however, blood type-O patients had shorter half-lives and time to 1% compared to non-blood type-O patients. In regression analysis, the PK of octocog alfa showed a statistically significant difference according to age, whereas the PK of ruri‑ octocog alfa pegol correlated with vWF:Ag. Only the frequency of rurioctocog alfa pegol use showed a statistically significant difference in relation to time to 1%, although the coefficient of determination was small.
Conclusion
This study confirmed significant interpatient variation in the PK of FVIII among Korean patients with hemophilia A. To achieve optimized prophylaxis, personalizing the regimen based on the PK profile of each individual patient is essential.

Keyword

Hemophilia A; FVIII; Pharmacokinetics; Prophylaxis; Korean

Figure

• 

  Fig. 1 Distribution of dose and frequency by quartiles of time to 1%. A Dose (IU/kg) of octocog alfa; (B) dose of rurioctocog alfa pegol; (C) frequency (injections per week) of octocog alfa; and (D) frequency of rurioctocog alfa pegol. The box in the plot represents the interquartile range (IQR), and the points extending from the box represent values that are 1.5 times greater than the IQR from the median value. R2 was calculated using a simple linear regression

• 

  Fig. 2 Distribution of dose and frequency by quartiles of half-life. A Dose (IU/kg) of octocog alfa; (B) dose of rurioctocog alfa pegol; (C) frequency (injections per week) of octocog alfa; and (D) frequency of rurioctocog alfa pegol. The box in the plot represents the interquartile range (IQR), and the points extending from the box represent values that are 1.5 times greater than the IQR from the median value. R2 was calculated using a simple linear regression

Reference

1. Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. 2020; WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. https://doi.org/10.1111/hae.14046. DOI: 10.1111/hae.14046. PMID: 32744769.

2. Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A. 2014; Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. https://doi.org/10.1111/jth.12672. DOI: 10.1111/jth.12672. PMID: 25059285.

3. Collins PW, Bjorkman S, Fischer K, Blanchette V, Oh M, Schroth P, Fritsch S, et al. 2010; Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost. https://doi.org/10.1111/j.1538-​7836.2009.03703.x. DOI: 10.1111/j.1538-7836.2009.03703.x.

4. Iorio A, Blanchette V, Blatny J, Collins P, Fischer K, Neufeld E. 2017; Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. J Thromb Haemost. https://doi.org/10.1111/jth.13867. DOI: 10.1111/jth.13867. PMID: 29119666.

5. 2023. MyPKFiT for Healthcare Professionals-User Manual Korean South Korea. Version 2.0. Takeda Pharmaceuticals U.S.A., Inc.;Lexington: https://sg-​prd-​hema.mypkf​it.com/documents/VAL-​378941_MYPKFIT3_HCP_USER_MANUAL_ko_KR.pdf.

6. Pasca S, Zanon E. 2019; Savings without changing: How to use the myPKfit® device to improve treatment strategies in a cohort of patients with haemophilia A. Thromb Res. https://doi.org/10.1016/j.thromres.2019.08.022. DOI: 10.1016/j.thromres.2019.08.022. PMID: 31505377.

7. Health Insurance Review and Assessment Service. Notice 2018-280. https://www.hira.or.kr/bbsDummy.do?brdBltNo=7152&brdScnBltNo=4&pgmid=HIRAA020002000100#none. Updated 2018. Accessed 25 Mar 2024.

8. Rayment R, Chalmers E, Forsyth K, Gooding R, Kelly AM, Shapiro S, et al. 2020; Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B. Br J Haematol. https://doi.org/10.1111/bjh.16704. DOI: 10.1111/bjh.16704. PMID: 32390158.

9. MASAC #267-MASAC Recommendation Concerning Prophylaxis for Hemophilia A and B with and without Inhibitors. https://www.hemophilia.org/healthcare-​professionals/guidelines-​on-​care/masac-​documents/masac-​document-​267-​masac-​recommendation-​concerning-​prophylaxisfor-​hemophilia-a-​and-b-​with-​and-​without-​inhibitors. Updated 2022. Accessed 25 Mar 2024.

10. Carcao MD, Chelle P, Clarke E, Kim L, Tiseo L, Morfini M, et al. 2019; Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference? J Thromb Haemost. https://doi.org/10.1111/jth.14469. DOI: 10.1111/jth.14469. PMID: 31038793.

11. Huang K, Wang Y, Zhen Y, Li G, Wu X, Zhang N, et al. 2022; Inter-individual variability in pharmacokinetics and clinical features in pediatric patients with severe hemophilia A. Thromb Res. https://doi.org/10.1016/j.thromres.2022.03.008. DOI: 10.1016/j.thromres.2022.03.008. PMID: 35305529.

12. Björkman S. 2013; Comparative pharmacokinetics of factor VIII and recombinant factor IX: for which coagulation factors should half-life change with age? Haemophilia. https://doi.org/10.1111/hae.12253. DOI: 10.1111/hae.12253. PMID: 24165155.

13. Machin N, Lim MY. 2021; Evidence-Based Minireview: For overweight or obese persons with hemophilia A, should factor VIII dosing be based on ideal or actual body weight? Hematology Am Soc Hematol Educ Program. https://doi.org/10.1182/hematology.2021000317. DOI: 10.1182/hematology.2021000317. PMID: 34889357. PMCID: PMC8791112.

14. Tiede A, Cid AR, Goldmann G, Jiménez-Yuste V, Pluta M, Lissitchkov T, et al. 2020; Body mass index best predicts recovery of recombinant factor VIII in underweight to obese patients with severe haemophilia A. Thromb Haemost. https://doi.org/10.1055/s-​0039-​3400745. DOI: 10.1055/s-0039-3400745.

15. Suzuki N, Hirakawa A, Kishimoto M, Kanematsu T, Ogawa M, Kiyoi H, et al. 2017; Retrospective analysis of in vivo recovery and clearance during continuous infusion of recombinant factor VIII products: a single-institution study. Haemophilia. https://doi.org/10.1111/hae.13082. DOI: 10.1111/hae.13082. PMID: 27704637.

16. Seo MH, Lee WY, Kim SS, Kang JH, Kang JH, Kim KK, et al. 2019; Corrigendum: 2018 Korean Society for the Study of Obesity Guideline for the Management of Obesity in Korea. J Obes Metab Syndr. https://doi.org/10.7570/jomes.2019.28.2.14. DOI: 10.7570/jomes.2019.28.2.143. PMID: 31294348. PMCID: PMC6604844. PMID: 51a392b51f72440ca296050e502d2bd8.

17. A healthy lifestyle - WHO recommendations. https://www.who.int/europe/news-​room/fact-​sheets/item/a-​healthy-​lifestyle---​who-​recommendations. Updated 2010. Accessed 25 Mar 2024.

18. Lalezari S, Martinowitz U, Windyga J, Enriquez MM, Delesen H, Schwartz L, et al. 2014; Correlation between endogenous vWF: Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-timesweekly prophylaxis with rFVIII-FS. Haemophilia. https://doi.org/10.1111/hae.12294. DOI: 10.1111/hae.12294. PMCID: PMC4233978.

19. Swystun LL, Lillicrap D. 2023; Current understanding of inherited modifiers of FVIII pharmacokinetic variation. Pharmgenomics Pers Med. https://doi.org/10.2147/PGPM.S383221. DOI: 10.2147/PGPM.S383221. PMID: 36998673. PMCID: PMC10046206.

20. Turecek PL, Johnsen JM, Pipe SW, O'Donnell JS. iPATH study group. 2020; Biological mechanisms underlying inter-individual variation in factor VIII clearance in haemophilia. Haemophilia. https://doi.org/10.1111/hae.14078. DOI: 10.1111/hae.14078. PMID: 32596930. PMCID: PMC7496649.

21. Vlot AJ, Mauser-Bunschoten EP, Zarkova AG, Haan E, Kruitwagen CL, Sixma JJ, et al. 2000; The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A. Thromb Haemost. 83(1):65–9. DOI: 10.1055/s-0037-1613759. PMID: 10669157.

22. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR. 1987; The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. https://doi.org/10.1182/blood.V69.6.1691.1691. DOI: 10.1182/blood.V69.6.1691.1691. PMID: 3495304.

23. Fischer K, Pendu R, van Schooten CJ, van Dijk K, Denis CV, van den Berg HM, et al. 2009; Models for prediction of factor VIII half-life in severe haemophiliacs: Distinct approaches for blood group O and non-O patients. PLoS ONE. https://doi.org/10.1371/journal.pone.0006745. DOI: 10.1371/journal.pone.0006745. PMID: 19707594. PMCID: PMC2727052. PMID: d8a694feac484d95ad255c101628da1c.

24. Health Insurance Review and Assessment Service. Notice 2023-146. Recombinant blood coagulation factor VIII, Beroctocog alfa, Moroctocog alfa. https://www.hira.or.kr/rc/insu/insuadtcrtr/InsuAdtCrtrPopup.do?mtgHmeDd=20230801&sno=1&mtgMtrRegSno=0001. Updated 2023. Accessed 25 Mar 2024.

25. Health Insurance Review and Assessment Service. Notice 2023-146. Recombinant blood coagulation factor VIII-Fc fusion protein Efmoroctocog α, Recombinant blood coagulation factor VIII, Rurioctocog α pegol, Lonoctocog alfa. https://www.hira.or.kr/rc/insu/insuadtcrtr/InsuAdtCrtrPopup.do?mtgHmeDd=20230801&sno=1&mtgMtrRegSno=0002. Updated 2023. Accessed 25 Mar 2024.